The results presented in this study indicated that neurosurgeons may need to change how they approach tumor removal and, when safe, include non-contrast-enhancing tumor during resection to achieve maximal resection.
In observing individuals aged 65 and older suffering from a recent nonmetastatic cancer, researchers indicated that there is a need to change attitudes toward aging and older people.
The biologic license application is supported by data from the phase II ZUMA-2 trial, which is currently assessing the CAR T-cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
The agency granted full approval to pemetrexed for injection (Pemfexy), a liquid injection and branded alternative to Alimta, for nonsquamous NSCLC.
Researchers found that targeting BCL-W in Burkitt lymphoma and diffuse large B-cell lymphoma may not offer wide-ranging therapeutic benefit.
The aim of this Chinese study was to evaluate the influencing factors of perioperative renal function change and their relationship with prognosis in patients with renal cell carcinoma and tumor thrombus after nephrectomy and thrombectomy.
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
A recent study found that patients with stage III breast cancer did not benefit from high-dose chemotherapy, nor did it impact long-term risks of major cardiovascular events.
Calibr received approval from the FDA to move forward with an investigational new drug to treat relapsed/refractory B-cell malignancies with a switchable CAR T-cell therapy.
The study is evaluating the oral inhibitor for patients with relapsed or refractory follicular lymphoma.
Researchers indicated that a lack of understanding of the mechanism and efficacy of PD-1/PD-L1 inhibitors is the major barrier for prescription of these inhibitors in Chinese tumor treatment-related departments.
The authors indicated that prospective clinical trials investigating DTIC-based systemic chemotherapies and liver-directed treatments are necessary to validate their findings.
ASCO named the advance in their annual report, Clinical Cancer Advances: ASCO’s Annual Report on Progress Against Cancer, highlighting novel advances and listing research priorities for the cancer community.
Researchers indicated that using observed incidence rates from patients with colorectal cancer alone to assess potential screening outcomes may underestimate cancer prevention benefits.
Inconsistencies observed by researchers on these websites indicated that efforts are needed to improve website content and readability.